Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP) Talks about Drug Delivery Platform, Hill Street Beverage Deal and Human Clinical Trial Results

Delta, Kelowna, BC – August 1, 2018 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its “potcast” site, release today’s edition of its series, potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP)

Today’s podcast overview/transcript:

Good morning and welcome to another potcast – looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today I will be talking with Chris Bunka the CEO of Lexaria Biosciences Corp. trading on the CSE as LXX and the OTC as LXRP.

Lexaria has developed a new disruptive drug delivery platform: DehydraTECH The Company’s patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally by masking unwanted tastes, reducing the time of onset, avoiding first-pass liver metabolism and increasing bio-absorption by 5-10X.

Interview highlights:

Can you explain in simple terms how the company’s delivery technology DehydraTECH™ works and some of the applications for the technology?

Chris Bunka:

“Our technology can be thought of as a dinner plate, we make a high-tech dinner plate. What you put on that is up to you. Our plate helps to pile that drug on and get it into your body more effectively. Our tech is based on some well-known bio chemistry which it’s the body’s propensity to absorb long chain fatty acids, similar to sunflower oil or avocado oil. We then “crazy glue” the long chain fatty acid to the side of the API. When you use our tech, you smell and taste the oleic acid, which has no taste and smell and masks the smell and taste of, in this case cannabinoids.”


Your company has issued and pending patents in over 40 countries around the world. That is impressive and somewhat unusual to find in a company of your size, so can you talk about your Intellectual property and licensing strategy?

Chris Bunka:

“We have 49 patents pending in 43 countries around the world and 8 patents granted with regards to DehydraTECH. We’re a small company but we punch above our weight. We are perhaps the only company our size that has completed all in vitro, in vivo and human clinical studies. We recently released a human clinical study that was conducted in Europe using our turbo CBD hemp oil product. In that study we demonstrated that we are able to deliver much more cannabidiol into a human being and much more quickly. We compared the data to a previous study done by Mount Sinai Hospital with a cannabidiol provided by GW Pharmaceuticals (NASDAQ: GWPH)  . At the 30-minute mark, using our turbo CBD, we had over 900% more cannabidiol in blood then they did.”

Recent news:

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules


The company is forming four new wholly-owned subsidiaries, one each for the pharmaceutical, nicotine, hemp, and cannabis industries. Can you talk about this strategy and what it means for the bigger picture?

Chris Bunka:

 “We realize that companies in the pharmaceutical industry or the nicotine industry even today may not want to have any association to the cannabis industry, which was one of the reasons we wanted to build a fence around our different intellectual property assets. We think this also a good deal for our shareholders as it gives us the opportunity to take those subsidiaries down slightly different paths with separate financing which adds versatility to the company, minimizes shareholder dilution and helps us conduct business with a broader swath of fortune 500 and global companies.”


On your website you say the legal cannabinoid consumer products space is expected to show Compounded Annual Growth Rate of more than 25% through 2021 in North America. Do you see that increasing based on federal legalization here this fall and the push for federal legalization in the US? And where do you see this industry ten years out ?

Chris Bunka:

 “The general answer is yes. I think the growth rates for cannabinoids edibles is going to be strongly double digit for the next years to come. I think as the market matures to embrace the “fat part’ of the demand curve, you’re going to see huge growth in consumer-friendly methods of ingesting cannabis. I don’t think most people realize we are in the first or second inning. You’re going to need the development of edibles legislation, international markets, international acceptance and societal acceptance. I wouldn’t be surprise to see double digit growth for a decade or more and in ten years I wouldn’t be surprise to see cannabis industry bigger then beer or wine.”

Recent news : Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

If you would like to be a guest or sponsor this podcast contact

Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP)

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Sign up to get the news alerts including the daily podcast and transcript for Investor ideas potcasts

Subscribe to the new cannabis podcast series:

Or visit


To hear more podcasts visit: podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About – News that Inspires Big Investing Ideas is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the Stock Guru daily podcast on Support and Resistance Trading.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Disclosure Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast starting July 5 2018 more info

Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Please read privacy policy:

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at

Follow us on Social Media



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *